JDD Spotlight: Dupilumab Shows Rapid, Sustained Relief for Lichenification in AD
A new pooled analysis from five clinical trials has revealed that dupilumab significantly improves lichenification in moderate to severe atopic dermatitis across all ages and racial groups. Starting as early as week 1 in adults and adolescents, and week 2 in children, patients treated with dupilumab experienced rapid and sustained improvements compared to placebo. These findings could refine your approach to managing stubborn lichenification in AD.
